LUCIUS 卢修斯 达克替尼 Dacomitinib细胞肺癌

达克替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Dacomitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

Each film-coated tablet contains

细胞肺癌

DacomitiniD ...........

LUCiUS

LuctDac is a kinase inhibitor indicated for

PHARMACEUTICALS

the first-line treatment of patients with
metastatic non-small cell lung cancer
(NSCLC) with cpidermal growth factor

Rx Only

receptor(EGFR) exon 19 deletion or exon
21L858R substitution mutations as detected

LuciDac

by an FDA-approvedtest
Dosage and Use:
Recommended Dosage: 45 mg orally onc
daily with or without food.

FDA批准

Storage: in a dry place and store at 20℃ 1o

Dacomitinib Tablets

Warning

45m

Keep medicine out of reach of Children. Do
not administer LuciDac during Pregnancy
and Lactation
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:
LOCIUS

权威认证

Thongmang village. Xaythany district.
Vientiane Capital, Laos
www.lucius.la
Warning: To be sold bv retail on oreserintion
yscians only, and as directed

30 Tablets

口碑质量

适应症:
适用于一线治疗经FDA批准的检测方法检测为表皮生长
因子受体(EGFR)外显子19缺失或外显子21L858R替代

突变的转移性非小细胞肺癌(NSCLC)的患者。
推荐剂量:
1、每日口服一次,每次45mg,直至疾病进展或出现不可
接受的毒性。
2、随餐或空腹均可。